Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for ALG and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ALG and 80,000+ other tickers.
See exactly how ALG's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ALG and 80,000+ other tickers.
Alamo Group Inc. is a global enterprise specializing in the design, production, distribution, and servicing of equipment crucial for managing vegetation and maintaining public and private infrastructure. It serves a broad international clientele spanning governmental agencies, industrial operations, and agricultural businesses. The company operates through two main divisions: Vegetation Management Division: This segment provides a comprehensive range of machinery and associated components for controlling plant growth and preparing land. Offerings include robust, hydraulically-powered and…
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that dosing has been initiated in the Phase 1 study of ALG-170675, an investigational next-generation antisense oligonucleotide (ASO) being evaluated for functional cure in the treatment of chronic hepatitis B virus (HBV) infection. The study is being conducted in China by Xiamen Amoytop Biotech Co., Ltd. (“Amoytop”), who maintain rights in Greater China.
Deere, Kubota, CNH, AGCO and Alamo have been highlighted in this Industry Outlook article.
Alamo Group Inc. (ALG) Q2 2026 Earnings Call Transcript
Alamo Group NYSE: ALG reported second-quarter 2026 net sales of $415.7 million, up 7.6% from a year earlier, as acquisitions and modest organic growth supported results. Organic net sales rose 1.3%, while adjusted diluted earnings per share increased 7.2% to $2.82.
The Manufacturing - Farm Equipment industry stocks DE, KUBTY, CNH, AGCO and ALG are set to benefit from demand for agricultural machinery driven by the need to feed a growing global population.